Population structure and antibiotic resistance profiles of Mycobacterium tuberculosis isolates from Ibadan, Nigeria (2019-2020): a pilot study to improve affordable molecular diagnostic tools

尼日利亚伊巴丹结核分枝杆菌分离株的群体结构和抗生素耐药性谱(2019-2020 年):一项旨在改进经济型分子诊断工具的试点研究

阅读:1

Abstract

Nigeria ranks as the sixth country globally and the first in Africa with the highest burden of tuberculosis (TB) infection. The emergence and spread of multidrug-resistant TB (MDR-TB) strains have posed significant challenges to effective disease management in the country. In this study, 55 Mycobacterium tuberculosis (MTB) isolates from patients attending a hospital in Ibadan city (Nigeria) were selected. MTB isolates were analyzed using PCR amplification of gene fragments associated with antibiotic resistance, followed by Sanger sequencing and bioinformatics analysis. Additionally, MIRU-VNTR genotyping was performed to address population structure and transmission dynamics. Results show an association between mutations in the rpoB, inhA and gyrA genes and phenotypic resistance to rifampicin, isoniazide and fluoroquinolones in a significant percentage of the MTB isolates. However, an extended panel of genes would enable a better characterization of antibiotic resistance. The population structure of MTB in Ibadan, as determined by using MIRU-VNTR, revealed that 96.1% of the strains belong to lineage 4, distributed in the following sublineages: Uganda I (47.1%), LAM (21.6%), Cameroon (17.6%), and Ghana (9.8%). Meanwhile, 3.9% of the strains correspond to lineage 5 (L5), West African-1 sub-lineage. The population structure was very heterogeneous and no active transmission clusters were detected. Overall, this pilot study demonstrated the utility of cost-effective molecular tools in enhancing TB surveillance and control programs in settings where whole-genome sequencing (WGS) is still an economical challenge.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。